RecruitingNot Applicable

Exosomes in Rectal Cancer

United States30 participantsStarted 2018-02-13

Plain-language summary

The primary aims of this study is to characterize exosomal biomarker levels in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation therapy. Compare rates of exosomal expression before during and after chemoradiation therapy with pathologic response rates at the time of APR or LAR. The researchers will also examine the functionality of these exosomes in malignant colonic organoids and mouse models of colorectal cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male and Female Patients aged 18 and older * histologically proven diagnosis of rectal adenocarcinoma * will be receiving neoadjuvant chemoradiation therapy prior to a planned definitive surgical resection Exclusion Criteria: * Age less than 18. * Patients who are unable or unwilling to undergo definitive surgery. * Patients with a prior history of pelvic external beam radiation, brachytherapy, or chemotherapy. * Patients with a prior history of cancer (excluding non-melanoma skin cancers). * Patients who are immunocompromised.

What they're measuring

Exosomal Biomarkers Assessment

Timeframe: up to 10 years after treatment completion

Trial details

NCT IDNCT03874559

SponsorUniversity of Kansas Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-02-01

Contact for this trial

Leah K Miller, MS

913-588-3670 lmiller25@kumc.edu

View on ClinicalTrials.gov More Rectal Cancer trials